Sihuan Pharmaceutical Holdings Group Gestione
Gestione criteri di controllo 4/4
Sihuan Pharmaceutical Holdings Group Il CEO è Weicheng Guo, nominato in Oct2014, e ha un mandato di 10.08 anni. la retribuzione annua totale è CN¥ 3.00M, composta da 100% di stipendio e 0% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.12% delle azioni della società, per un valore di HK$ 8.29M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.1 anni e 8.7 anni.
Informazioni chiave
Weicheng Guo
Amministratore delegato
CN¥3.0m
Compenso totale
| Percentuale dello stipendio del CEO | 100.0% |
| Mandato del CEO | 10.1yrs |
| Proprietà del CEO | 0.1% |
| Durata media del management | 2.1yrs |
| Durata media del Consiglio di amministrazione | 8.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You
Oct 02
Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?
Sep 30Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year
May 31Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
May 27A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥38m |
| Mar 31 2024 | n/a | n/a | -CN¥46m |
| Dec 31 2023 | CN¥3m | CN¥3m | -CN¥54m |
| Jun 30 2023 | n/a | n/a | -CN¥2b |
| Mar 31 2023 | n/a | n/a | -CN¥2b |
| Dec 31 2022 | CN¥3m | CN¥3m | -CN¥2b |
| Jun 30 2022 | n/a | n/a | -CN¥144m |
| Mar 31 2022 | n/a | n/a | CN¥141m |
| Dec 31 2021 | CN¥6m | CN¥6m | CN¥427m |
| Sep 30 2021 | n/a | n/a | CN¥681m |
| Jun 30 2021 | n/a | n/a | CN¥945m |
| Mar 31 2021 | n/a | n/a | CN¥727m |
| Dec 31 2020 | CN¥6m | CN¥6m | CN¥508m |
| Sep 30 2020 | n/a | n/a | -CN¥14m |
| Jun 30 2020 | n/a | n/a | -CN¥537m |
| Mar 31 2020 | n/a | n/a | -CN¥2b |
| Dec 31 2019 | CN¥6m | CN¥6m | -CN¥3b |
| Sep 30 2019 | n/a | n/a | -CN¥2b |
| Jun 30 2019 | n/a | n/a | -CN¥1b |
| Mar 31 2019 | n/a | n/a | CN¥238m |
| Dec 31 2018 | CN¥6m | CN¥6m | CN¥2b |
| Sep 30 2018 | n/a | n/a | CN¥1b |
| Jun 30 2018 | n/a | n/a | CN¥1b |
| Mar 31 2018 | n/a | n/a | CN¥1b |
| Dec 31 2017 | CN¥6m | CN¥6m | CN¥1b |
Compensazione vs Mercato: La retribuzione totale di Weicheng ($USD 418.80K ) è circa la media per le aziende di dimensioni simili nel mercato Hong Kong ($USD 500.67K ).
Compensazione vs guadagni: La retribuzione di Weicheng è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Weicheng Guo (60 yo)
10.1yrs
Mandato
CN¥3,000,000
Compensazione
Dr. Weicheng Guo co-founded Sihuan Pharmaceutical Holdings Group Ltd. and has been its Chief Executive Officer since October 20, 2014. Dr. Guo is responsible for the overall operations of Sihuan Pharmaceut...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 18.5yrs | CN¥7.00m | 5.34% HK$ 363.1m | |
| Deputy Chairman & CEO | 10.1yrs | CN¥3.00m | 0.12% HK$ 8.3m | |
| Deputy CEO | 2.1yrs | CN¥5.05m | Nessun dato | |
| Executive Director | 4yrs | CN¥646.00k | 2.14% HK$ 145.3m | |
| Joint Company Secretary & Executive Director | 2.1yrs | CN¥1.77m | Nessun dato | |
| Joint Company Secretary | 2.1yrs | Nessun dato | Nessun dato | |
| Deputy General Manager | no data | CN¥4.26m | Nessun dato |
2.1yrs
Durata media
60yo
Età media
Gestione esperta: Il team dirigenziale di 460 è considerato esperto (durata media dell'incarico 2.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 18.5yrs | CN¥7.00m | 5.34% HK$ 363.1m | |
| Deputy Chairman & CEO | 18.5yrs | CN¥3.00m | 0.12% HK$ 8.3m | |
| Deputy CEO | 2.1yrs | CN¥5.05m | Nessun dato | |
| Executive Director | 6.6yrs | CN¥646.00k | 2.14% HK$ 145.3m | |
| Joint Company Secretary & Executive Director | 6.6yrs | CN¥1.77m | Nessun dato | |
| Independent Non-Executive Director | 11.2yrs | CN¥371.00k | Nessun dato | |
| Independent Non-Executive Director | 10.8yrs | CN¥371.00k | Nessun dato | |
| Independent Non-Executive Director | 1.6yrs | CN¥202.00k | Nessun dato |
8.7yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 460 sono considerati esperti (durata media dell'incarico 8.7 anni).